Please assess the completion status of the following clinical trial:

Trial Title: Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* female patients~* 21 years of age or older~* histologically/cytologically confirmed carcinoma of the breast~* documented locally recurrent or metastatic disease not amenable to curative surgery or radiotherapy~* either one, two or three prior chemotherapy regimens~* prior treatments including both an anthracycline and a taxane and patient no longer candidate for these drugs~* measurable or non-measurable disease according to RECIST 1.1~* Karnofsky performance score of at least 70 %~* adequate haematological, hepatic and renal functions~* ECG without clinically relevant abnormality~Exclusion Criteria:~* known or clinical evidence of brain metastasis or leptomeningeal involvement~* pulmonary lymphangitis or symptomatic pleural effusion~* any serious, concurrent uncontrolled medical disorder~* history of second primary malignancy~* preexisting motor/sensory peripheral neuropathy~* known history of HIV infection~* prior therapy with capecitabine and/or vinca-alkaloids~* history of severe hypersensitivity to vinca alkaloids and/or to fluoropyrimidine or contra indication to any of these drugs~* known or suspected dihydropyrimidine dehydrogenase (DPD) deficiency~* pregnancy or breast feeding

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vinflunine plus Capecitabine (Type: EXPERIMENTAL): Patients received (in combination with capecitabine)~• Vinflunine at the dose of 280 mg/m² and as a 20-minute IV. infusion on day 1 of each cycle repeated every 3 weeks.
- Capecitabine single-agent (Type: ACTIVE_COMPARATOR): Capecitabine at the dose of 825mg/m² per os twice per day each morning and each evening for 14 consecutive days beginning on day 1 of each cycle repeated every 3 weeks (self-administered).

Based on this trial design, predict the completion outcome and termination type (if applicable).